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Strengths and limitations of this study
 ► It is possible for physicians to interpret verbal au-
topsy (VA) data to ascertain cases of premature 
mortality due to uncontrolled hyperglycaemia with 
reasonable inter-rater reliability.
 ► A simple, validated algorithm can be used to find 
cases of uncontrolled hyperglycaemia using VA data.
 ► Methods can only be used where VA systems exist.
 ► There was no gold standard laboratory diagnosis to 
confirm our findings.
AbStrACt
Objectives Verbal autopsy (VA) is a useful tool to 
ascertain cause of death where no other mechanisms 
exist. We aimed to assess the utility of VA data to ascertain 
deaths due to uncontrolled hyperglycaemia and to develop 
a weighted score (WS) to specifically identify cases. Cases 
were identified by a study or site physician with training 
in diabetes. These diagnoses were also compared with 
diagnoses produced by a standard computer algorithm 
(InterVA-4).
Setting This study was done using VA data from the 
Health and Demographic Survey sites in Agincourt in rural 
South Africa. Validation of the WS was done using VA data 
from Karonga in Malawi.
Participants All deaths from ages 1 to 49 years between 
1992 and 2015 and between 2002 and 2016 from 
Agincourt and Karonga, respectively. There were 8699 
relevant deaths in Agincourt and 1663 in Karonga.
results Of the Agincourt deaths, there were 77 study 
physician classified cases and 58 computer algorithm 
classified cases. Agreement between study physician 
classified cases and computer algorithm classified cases 
was poor (Cohen’s kappa 0.14). Our WS produced a 
receiver operator curve with area under the curve of 0.952 
(95% CI 0.920 to 0.985). However, positive predictive 
value (PPV) was below 50% when the WS was applied 
to the development set and the score was dominated 
by the necessity for a premortem diagnosis of diabetes. 
Independent validation showed the WS performed 
reasonably against site physician classified cases with 
sensitivity of 86%, specificity of 99%, PPV of 60% and 
negative predictive value of 99%.
Conclusion Our results suggest that widely used VA 
methodologies may be missing deaths due to uncontrolled 
hyperglycaemia. Our WS may offer improved ability to 
detect deaths due to uncontrolled hyperglycaemia in large 
populations studies where no other means exist.
IntrOduCtIOn
Hyperglycaemic emergencies, namely 
diabetic ketoacidosis (DKA) and hyper-
glycaemic hyperosmolar state (HHS), are 
preventable causes of premature mortality. 
Both of these conditions occur in individuals 
with uncontrolled diabetes mellitus and are 
usually precipitated by intercurrent illness.1 
DKA is classically seen in patients with type 1 
diabetes and has inadequate insulin therapy 
as a frequent precipitant; HHS is classically 
seen in type 2 diabetes. Either of these hyper-
glycaemic emergencies may be seen in either 
type of diabetes.1 DKA is the leading cause 
of mortality in younger people with type 1 
diabetes2 and mortality from HHS ranges 
from 10% to 20%.3
Mortality from hyperglycaemic emergencies 
has decreased significantly in high-income 
countries (HICs),1 4 largely due to improved 
diagnosis and treatment of these conditions 
and underlying diabetes. By contrast, deaths 
from acute complications of uncontrolled 
hyperglycaemia remain high in lower and 
middle-income countries (LMICs).5–8 While 
delays in presenting to health facilities 
undoubtedly contribute, deaths from hyper-
glycaemic emergencies are also an indicator 
of an unmet need for diabetes care after that 
care is sought. Long-term glycaemic control 
as well as rapid diagnosis and treatment of 
decompensated diabetes would significantly 
reduce mortality from these conditions.
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Little data exist on the mortality rates in hypergly-
caemic emergencies in LMICs and the data that do exist 
have often been obtained from hospital records7 8 and 
therefore may underestimate true mortality as they do not 
capture those deaths that occur out of hospital. Verbal 
autopsy (VA) has been developed to address the deficit 
of accurate, countrywide, reporting of cause of death in 
many LMICs9 10 and may improve mortality estimates in 
these conditions.
VA from population samples is a useful tool to ascer-
tain causes of mortality and trends thereof.11–13 During 
VA, a respondent—usually a relative—who cared for the 
deceased during his or her last illness is asked a set of 
standard questions by a trained data collector about the 
illness.14 15 VA reports are either reviewed by physicians 
who assign a cause of death or, increasingly, processed 
automatically by computer models to derive likely causes 
of death. Such models (eg, InterVA-4) are derived using 
a mixture of data and expert opinion.16 They have been 
shown to be reasonably reliable in determining causes of 
death which are commonly seen, but data on reliability 
of these methods for estimating causes of death for less 
prevalent diseases are lacking.11 16–18
Where there are classic features of an acute death 
from hyperglycaemia (symptom combinations including 
diagnosis of diabetes, increased thirst, increased urine 
output, coma and so on), it is relatively straightforward 
for either a reviewing physician or an automated model 
like InterVA-4 to arrive at a high likelihood of diabetes as 
a cause of death. However, for many people living with 
diabetes, the symptoms occurring around the time of 
death may be less obvious, especially in contexts where 
symptoms of hyperglycaemia can be attributable to other, 
more common conditions. In these cases, increased 
index of reviewing physician suspicion, for example due 
to greater exposure to or knowledge of the disease, may 
improve detection of the condition.
We therefore aimed to assess ability of the VA meth-
odology, using InterVA-4 algorithm determined cause 
of death, to detect deaths attributable to uncontrolled 
hyperglycaemia, as compared with diagnoses made by 
a study physician with experience of diabetes care in 
a LMIC setting. A further aim was to derive and test a 
weighted score (WS)—which could later be applied to 
other settings using VA reports—for detecting deaths due 
to uncontrolled hyperglycaemia and validate this WS in 
VA data from an independent data set. Other aims were 
to compare our WS and the study physician diagnoses. 
We limited our age range between 1 and 49 years with an 
aim of focusing particularly on premature mortality due 
to uncontrolled hyperglycaemia.
MethOdS
Setting and VA methodology
Our study was done using VA data from the Agincourt 
Health and Socio-Demographic Surveillance System 
(HDSS) and validated using data from the Karonga HDSS 
in Malawi.19 20 The Agincourt HDSS is based in the Agin-
court sub-district of rural, northeast South Africa, near 
the Mozambique border; the Karonga HDSS is based in 
the south of Karonga district, in rural northern Malawi. 
From Agincourt, we used VA data collected on annual 
census visits between 1992 and 2015; from Karonga, 
we used VA data collected at household visits initiated 
after reporting of a death by a community informant at 
monthly reporting session between 2002 and 2016. VA 
methodology is described in detail elsewhere.16 In brief, 
for any death, household members are approached and 
asked to take part in an interview based on standard WHO 
questionnaires and administered by a local, trained, data 
collector or medical assistant. VA questionnaires consist of 
responses (which are converted to binary for processing 
with InterVA-4) to a range of questions on signs, symp-
toms and diagnoses during the terminal illness. Some 
VAs (eg, those in Agincourt and Karonga) also have a 
‘free text’ section where respondents are able to freely 
describe circumstances leading up to the death. In Agin-
court, prior to 2010, cause of death was defined by physi-
cian review of each VA. After 2010, all causes of death 
have been determined using InterVA computer algo-
rithms; all VAs have also been retrospectively formatted 
for input into InterVA-4 with binary variables (presence of 
symptom or absence/unknown). In Karonga, both physi-
cian review and computer models are used; two physi-
cians review—blind to each other’s coding—and allocate 
underlying cause of death as well as direct and contribu-
tory causes.20 Where there is discrepancy between physi-
cians, a third reviewer considers the VA and the responses 
of the first two physicians and decides on the cause(s) of 
death to be coded. Questionnaire and free text responses 
are de-identified and stored in electronic databases.
Participant selection and creation of study physician coded 
data set
Given the rarity of presenting with uncontrolled hyper-
glycaemia in infants under 1 year old, the increased like-
lihood of deaths being due to other competing causes 
in those of older years, and our focus on premature 
mortality, we agreed a priori to restrict our sample age 
range to deaths occurring between 1 and 49 years of age, 
inclusive. To enable later application of the WS to other 
VA data sets, we aligned our age range selection with 
the WHO 2012 standard VA age groups and therefore 
included those in VA age groups ‘under 5’ (1–4), ‘child’ 
(5–14) and ‘adult’ (15–49).
Data sets that use clinical data including hospital diag-
noses and laboratory results to provide a gold standard 
cause of death have been developed and enable testing of 
standard VA methodologies. However, the VA input param-
eters collected in these data sets are not complete,12 21 
and although fields of use for diagnosing diabetes—for 
example polyuria and polydipsia—are present in stan-
dard VA questionnaires, they are not captured in these 
gold standard sets. We therefore created a study physi-
cian coded data set that was to act as our ‘gold standard’. 
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A clinician with experience in diabetes management in 
HICs and LMICs (SB) reviewed all data from VA records 
at Agincourt. Study physician classified cases were deter-
mined using responses to the answers to VA questions and 
examination of the free text. Cases were defined as those 
for whom uncontrolled hyperglycaemia would be accept-
able as the main cause of death on a standard UK death 
certificate. Any cases where the reviewing physician was 
unsure were discussed with clinical colleagues with exper-
tise in adult internal medicine, diabetes and endocri-
nology (AW, JD and MDW) until consensus was reached.
Given the likely rarity of study physician classified cases, 
we produced an enriched sample of cases for study physi-
cian review by searching the VA database for cases with 
features suggestive of uncontrolled hyperglycaemia as 
individual symptoms, symptom combinations or terms 
(chosen to reflect both chronic and acute symptoms of 
diabetes) as follows:
 ► Ante-mortem (AM) diagnosis of diabetes.
 ► Polyuria.
 ► Polydipsia.
 ► Weight loss combined with polyuria or polydipsia.
 ► Weight loss combined with polyuria or polydipsia and 
in combination with acute rapid breathing, abdom-
inal pain, confusion or coma.
 ► ‘Sugar’ or ‘diabetes’ in the free text search.
 ► Site-physician review indication of deaths due to 
diabetes (in Agincourt VA data prior to 2010).
Any cases that did not have any of the above features 
were thought clinically unlikely to have died from uncon-
trolled hyperglycaemia and were therefore categorised 
as deaths from other causes (hereafter termed ‘negative 
cases’).
Comparison of study physician classified cases with computer 
algorithm classified cases
We compared the predictive value of InterVA-4 (with posi-
tive cases termed computer algorithm classified cases) 
against study physician classified cases in the Agincourt 
data set using χ2 and used Cohen’s kappa as a measure 
of inter-rater correlation, with the recognition that the 
‘raters’ in this context included algorithms. As there is 
no InterVA-4 category of cause of death due to hypergly-
caemia, computer algorithm classified cases were defined 
as determined by InterVA-4 as being greater than 50% 
likely to be due to diabetes.
development of predictive score
After producing a set of study physician classified cases 
and negative cases, we tested the predictive value of 
VA-recorded variables. These variables were chosen after 
consensus was reached by study clinicians on which were 
likely to be seen in uncontrolled hyperglycaemia in clin-
ical practice (as either subacute or chronic features).22 
Additionally, we identified symptom variables which we 
agreed would reduce likelihood of a death being due to 
uncontrolled hyperglycaemia and which were captured 
by the VA questions. We performed univariable testing of 
each individual symptom for its ability to predict study 
physician classified cases using the χ2 test. Symptoms that 
were significant univariable predictors at p<0.1 (Pear-
son’s χ2) were entered into a multivariable binary logistic 
regression model using stepwise entry. A WS was then 
developed based on the relative beta-weights in the final 
multivariable model.
We constructed a receiver–operator characteristic 
(ROC) curve based on the relationship between the WS 
for each individual VA entry and study physician classi-
fication. We then determined the sensitivity, specificity, 
positive and negative predictive values (PPV and NPV) of 
the WS at various cut points.
Score validation
We used VA data from Karonga HDSS in Malawi to exter-
nally validate our WS. Cases above a cut point determined 
based on analysis of Agincourt data were extracted for 
review and these ‘WS classified cases’ were compared with 
Karonga site-physician classified cases.
In addition, and to allow for differences between 
Karonga site-physician diagnosis and one made by a physi-
cian with expertise in diabetes and experience in working 
in an LMIC setting, in a sample of 100 cases we compared 
WS classified cases with classification by an independent 
endocrinologist (AW, who determined independent 
physician classified cases (investigator physician classified 
cases)). These 100 cases were made up of all WS classified 
cases plus a random selection of cases not determined to 
be deaths due to uncontrolled hyperglycaemia .
We compared computer algorithm classified cases and 
study physician classified cases with WS classified cases 
using χ2. We also describe the predictive value of symp-
toms identified by multivariable analysis in determining 
computer algorithm classified cases.
determining timing of diagnosis of diabetes
For study physician classified cases or WS classified cases, 
we ascertained which had been diagnosed with diabetes 
prior to or during the final illness by examining responses 
to the VA question, ‘did the deceased have diabetes’ and 
examining the VA free texts. Cases where it was stated 
in the free text that diagnoses of diabetes were given, 
or patients were told their sugar levels were high in the 
final illness, with no noted history of diabetes on VA ques-
tion response were assumed to have been diagnosed in 
the final illness. We assumed that diabetes was diagnosed 
prior to the final illness in cases where it was stated in the 
free text that patients were known to have diabetes. Cases 
where there was no mention of diabetes in the free text 
were classified as unknown.
Statistical analysis
SPSS V.22 was used for all analyses.
Patient and public involvement
No patients were involved in this study.
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Figure 1 Study flow chart.
reSultS
determining study physician classified cases
There were 15 261 deaths occurring in the Agincourt 
HDSSs which had a VA report completed between 1992 
and 2015, of which 8699 were between the ages of 1 and 
49 years. After limiting cases to those with symptoms 
suggestive of uncontrolled hyperglycaemia, there were 
3708 cases which were reviewed by the study physician. 
There were two cases with missing data. Of all VA reports 
reviewed, 77 cases were determined as positive (study 
physician classified cases), 3626 were negative and 3 
were deemed indeterminate even after discussion among 
investigators. Figure 1 shows the flow of classification of 
VA cases at Agincourt into study physician classified cases 
and negative cases.
Comparison of study physician classified cases with computer 
algorithm classified cases
There were 58 computer algorithm classified cases. χ2 
testing showed that there was dependence between study 
physician classified cases and computer algorithm clas-
sified cases (Pearson’s χ2 of 176, 1 degree of freedom, 
p<0.001); however although they were associated on the 
χ2 test (online supplementary appendix table 1), kappa 
showed poor concordance, with the VA algorithm not 
finding the majority of cases identified by the physician; 
Cohen’s kappa for inter-rater agreement was low at 0.14.
development of the WS
On discussion between investigators, we identified AM 
diagnosis of diabetes, polyuria, polydipsia, sunken eyes, 
weight loss, wasting, acute rapid breathing, abdominal 
pain or acute abdominal pain (which are two separate 
responses on VA), coma and confusion as being variables 
collected on VA which were likely to be seen in cases of 
deaths due to uncontrolled hyperglycaemia. In environ-
ments where tuberculosis and other respiratory condi-
tions are common causes of death, we did not consider 
that other symptoms of breathlessness captured on VA 
were likely to be discriminating enough for our purposes. 
Of our potential predictive variables, nine which were 
significantly associated with study physician classified 
cases on univariable testing—and thus entered into the 
multivariable regression analysis—were AM diagnosis 
of diabetes (p<0.001), polyuria (p=0.001), polydipsia 
(p<0.001), confusion (p<0.001), weight loss (p=0.001), 
chronic abdominal pain (p<0.001), abdominal pain 
(p<0.001), acute rapid breathing (p=0.095) and wasting 
(p=0.098) (online supplementary appendix table 2).
We identified 27 variables that were captured on the VA 
questions that were considered to decrease the clinical 
likelihood of the death being due to uncontrolled hyper-
glycaemia; these were HIV, tuberculosis (TB), chronic 
cough, cough, productive cough, bloody cough, TB 
combined with chronic cough, chronic fever, whooping 
cough, wheeze, night sweats, chronic diarrhoea, bloody 
diarrhoea, jaundice, haematemesis, haematuria, abdom-
inal mass, swollen abdomen, swollen legs, injury, died 
in labour, died 24 hours after labour, vaginal bleeding 
after menopause, kidney disease, liver disease, cancer 
or measles. Of these variables, on univariable testing, we 
found injury (p=0.021), TB combined with chronic cough 
(p=0.097), night sweats (0.032) and chronic diarrhoea 
(0.032) were significant negative predictors of positive 
cases. Haematuria (p=0.06) and measles (p=0.002) were 
significant predictors of study physician classified cases 
(table 1 and online supplementary appendix table 2). 
The positive association between cases and measles lacked 
face validity. However, haematuria could be a misunder-
standing of urinary frequency also seen in uncontrolled 
hyperglycaemia. We therefore entered TB combined with 
chronic cough, chronic diarrhoea, injury, night sweats 
and haematuria into the regression analysis.
The WS was produced using variables that were signifi-
cantly associated with study physician classified cases on 
binary logistic regression analysis, scaled to the lowest 
positive beta weight and rounded up (or down) to the 
nearest whole number (table 1). This produced a ROC 
(figure 2) with an area under the curve of 0.952 (95% 
CI 0.920 to 0.985). Sensitivity, specificity, NPV and PPV 
of various cut points for the WS applied to the Agincourt 
data set and compared with study physician cases are 
shown in table 2.
We chose a cut point of 8 to identify cases with reason-
able specificity while maintaining sensitivity. Applying this 
cut point in the Agincourt data set gave 134 WS classified 
cases, thus 1.54% (134/8699) of all deaths were estimated 
due to uncontrolled hyperglycaemia. Characteristics of 
these deaths are shown in table 3. In particular, all had an 
AM diagnosis of diabetes recorded; 62 cases had diabetes 
diagnosed in the final illness and 24 cases had symptoms 
on the free text which were determined to be suggestive 
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Table 1 Binary logistic regression showing variables entered into the weighted score and derived score weights
Number of 
cases with 
symptom Beta SE P value
Weighting 
(beta/0.751)
Rounded 
weight
Ante-mortem diagnosis of diabetes 140 6.462 0.357 <0.001 8.6045273 9
Polyuria 265 1.542 0.583 0.008 2.05326232 2
Polydipsia 2539 1.406 0.353 <0.001 1.87217044 2
Confusion 1569 0.751 0.352 0.033 1 1
TB and chronic cough 944 −1.627 0.716 0.023 −2.1664447 −2
Chronic diarrhoea 992 −2.058 0.795 0.01 −2.7403462 −3
Constant – −7.114 0.357 <0.001 – –
TB, tuberculosis.
Figure 2 Receiver–operator characteristic curve for 
weighted score applied to study physician coded data set.
of uncontrolled hyperglycaemia. Of note, 138 of all VA 
deaths in the age range of interest from Agincourt had an 
AM diagnosis of diabetes—4 more than those detected by 
the algorithm.
Comparison of WS classified cases with computer algorithm 
classified cases
Online supplementary appendix table 1 shows the 
performance of our WS in comparison with InterVA-4. 
χ2 showed dependence (Pearson’s χ2 of 146, 1 degree of 
freedom, p<0.001), however, inter-rater agreement was 
poor (Cohen’s kappa).
Validation of the WS
We validated our WS using VA data from Karonga in 
Malawi. There were 3614 VA reports between 2001 and 
2016 and 1663 of these were from people between 1 and 
49 years old. Application of our WS to Karonga VA data 
and use of a cut point of 8 or above identified 20 cases 
of deaths due to uncontrolled hyperglycaemia (table 3). 
Comparison of these 20 WS classified cases with site physi-
cian classified cases (either as underlying or as contrib-
utory cause) showed 12 WS classified cases which were 
true positives; the Karonga site physician also identified 
an additional two case of deaths from diabetes which the 
algorithm did not detect; thus, giving a sensitivity of 86%, 
specificity of 99%, PPV of 60% and NPV of 99%.
Of the 20 WS classified cases, all were in the adult 
age group: 9 between 20 and 29, 5 between 30 and 39 
and 6 between 40 and 49 years of age. All cases had a 
premortem diagnosis of diabetes, and we determined 
that 4 of these diagnoses were made in the final illness 
(of note, 22 deaths in the whole Karonga VA data set for 
this age range had premortem diagnosis of diabetes). Ten 
relatives reported symptoms on the free text that were 
suggestive of uncontrolled hyperglycaemia, and for 7 of 
the 20 WS detected cases, relatives recalled being told by 
treating healthcare workers that the death was caused by 
diabetes (table 3).
Out of the 100 cases assessed, the external investigator 
physician (AW) determined that a total of 22 were due 
to uncontrolled hyperglycaemia, 74 deaths were not due 
to uncontrolled hyperglycaemia and 4 were unclassifiable 
due to missing data. Compared with the external investi-
gator physician, the WS gave 15 true positives and 7 false 
negatives. All site physician classified cases were deemed 
positive by the independent physician investigator. 
However, compared with the site physician, the indepen-
dent physician investigator determined that there were 
an additional nine deaths likely to be due to uncontrolled 
hyperglycaemia (kappa for inter-rater agreement=0.69).
Performance of clinically determined variables in detecting 
computer algorithm classified cases
Variables which we determined were clinically likely 
to increase or decrease chance of death due to uncon-
trolled hyperglycaemia were tested for association with 
computer algorithm classified cases. In univariable 
testing, we found AM diagnosis of diabetes (p<0.001), 
polyuria (p<0.001) and polydipsia (p<0.001) to be 
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Table 2 Sensitivity and specificity of the weighted score above different score cut points (summed weightings) as applied to 
Agincourt data and tested against study physician classification of cases
Cut point Number of deaths above cut point Sensitivity (%) Specificity (%) PPV (%) NPV (%)
5 169 83.54 98.91 39.05 99.85
6 138 82.27 99.15 47.10 99.84
7 136 82.28 99.17 47.79 99.84
8 134 82.28 99.20 48.01 99.84
9 133 81.01 99.20 48.12 99.82
NPV, negative predictive value; PPV, positive predictive value.
Table 3 Characteristics of people identified by the study physician and the algorithm as having died of diabetes
Agincourt Agincourt Karonga
study physician 
classified cases
weighted score 
classified cases 
(cut point >8)
weighted score 
classified cases 
(cut point >8)
Total 77 134 20
Infant 0 3 0
Under 5 6 6 0
Child 3 3 0
Adult 68 122 20
Female 38 71 12
Male 39 63 8
Any recorded AM diagnosis of diabetes 64 134 20
No AM diagnosis of diabetes 13 0 0
AM diagnosis of diabetes made in final illness 37 62 4
AM diagnosis of diabetes made prior to final illness 3 10 10
Unknown when AM diagnosis of diabetes made 24 62 6
AM, ante-mortem.
positive predictors in these cases. TB and chronic cough 
(p=0.025), wasting (p<0.001), sunken eyes (p=0.012), 
chronic diarrhoea (p=0.006), chronic cough (p<0.001), 
chronic fever (p=0.003), wheeze (p<0.001), productive 
cough (p=0.003), night sweats (p<0.001), abdominal 
swelling (p=0.048) and injury (p=0.03) were significant 
negative predictors of diabetes. Results of multivariable 
testing are shown in online supplementary appendix 
table 3. Online supplementary appendix table 1 shows 
the performance of InterVA-4 in comparison with the 
study physician categorisation.
dISCuSSIOn
There are several key findings from our study. The first is 
that compared with a physician classification of VA data, 
the widely used InterVA-4 algorithm performs poorly in 
detecting cases of deaths thought clinically likely due to 
uncontrolled hyperglycaemia. Reports from InterVA-4 on 
numbers of deaths due to diabetes should therefore be 
interpreted with caution. Second, we found that a large 
number of deaths due to uncontrolled hyperglycaemia 
received only a diagnosis of diabetes in their final illness, 
especially in the Agincourt sample. VA captures data from 
carers, rather than health records, and thus this finding 
may be overly negative. It is nevertheless troubling, and 
suggests that further investigation of health system’s 
ability to diagnose and manage diabetes is needed. Third, 
it was possible to develop a WS to detect cases of uncon-
trolled hyperglycaemia, that, at a cut point of greater 
than 8, had reasonable sensitivity and specificity. Our WS 
also had better agreement with study physician classified 
cases than the InterVA-4 model. On validation in an inde-
pendent data set, the score also showed good sensitivity 
and specificity for predicting deaths due to uncontrolled 
hyperglycaemia both when compared with site physician 
classified cases and investigator physician classified cases. 
However, the score was dominated by a premortem diag-
nosis of diabetes and it could be argued that inclusion 
of the other factors provided minimal further discrimina-
tory value. Apart from premortem diagnosis of diabetes, 
the predominant symptoms that our WS detected were 
related to uncontrolled hyperglycaemia (polydipsia and 
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polyuria). Our score, or indeed, VA cannot discriminate 
between deaths due to hyperglycaemia-related compli-
cations of type 1 or type 2 diabetes. Additionally, given 
recent evidence from HIC which suggests the fall in inci-
dence of type 1 diabetes with age may not be as steep as 
previously thought23 and, from sub-Saharan Africa, where 
there is some evidence that the peak age of presentation 
may be older than in other countries,24 25 limiting the age 
range of cases is unlikely to be a strategy to enable detec-
tion of cases of uncontrolled hyperglycaemia due to type 
1 diabetes.
As mentioned, we found that AM recording of a diag-
nosis of diabetes was the strongest predictor of a death 
being due to uncontrolled hyperglycaemia, in fact, 
using our score cut point of 8, it is not possible to assign 
diabetes as a cause of death without diabetes having been 
recorded on the VA report. This is a further limitation 
of our score, making it only applicable in settings where 
health systems are advanced enough to diagnose diabetes 
or report hyperglycaemia; unfortunately, in many LMICs, 
laboratory services are focused on detecting infectious 
rather than non-communicable diseases.26 This lack of 
diagnostic capacity also impacts on the ability of health 
systems to detect and treat diabetes to prevent untimely 
deaths. Even in countries with reasonable diagnostic 
ability, it may not be deployed early enough in the 
disease course to avert death.27 28 Such delayed diagnosis 
is reflected in our finding that diagnosis of diabetes was 
often made in the final illness, suggesting that the death 
could have been averted if diagnosis had been made 
earlier in the illness. Access to diagnostic testing has to 
be paired with an increased index of suspicion of the 
diagnosis early in the disease course. We also acknowl-
edge that even if diagnoses are made, hurdles of access 
to treatment still need to be overcome.29 30 Unfortunately, 
given the small numbers of deaths found in this study, we 
were not able to reliably look at temporal trends in access 
to care.
Although we found that our WS performance was 
substantially more reliable in ascertaining cases of deaths 
due to uncontrolled hyperglycaemia than InterVA-4 when 
applied to Agincourt, our study aim was to look specifi-
cally for this condition, and we produced an algorithm 
that was optimised to find cases. In contrast, InterVA-4 
takes into consideration numerous competing diseases to 
deliver an adequate performance to determine popula-
tion-level causes of death across a wide range of diseases16 
and was not developed to detect single diseases. Further-
more, while physicians use both presence and absence of 
symptoms to determine diagnoses, InterVA-4 predomi-
nately relies on presence of symptoms.31 It is also inter-
esting that there were differences between physicians 
in ascribing uncontrolled hyperglycaemia as a cause of 
death. These differences are likely to result from different 
exposure to disease prevalence and be influenced by the 
reason for examining the data; it would be expected that 
physicians who were used to dealing with a condition and 
who were specifically looking for that condition would 
find a greater prevalence of that condition.32–34 However, 
that there was reasonable agreement between the investi-
gator physician (AW) and the algorithm with the Karonga 
site physician diagnoses is reassuring.
There are several limitations of our study. The lack of 
a gold standard data set which contained both confirmed 
clinical diagnosis and relevant VA parameters necessi-
tated our use of a physician to ascertain cases, and without 
laboratory results, the diagnosis can never be certain. To 
enrich the data set for clinical review with likely cases, we 
also preselected cases that had one or more responses 
on VA which could suggest the diagnosis; although it is 
unlikely that deaths with no symptoms of uncontrolled 
hyperglycaemia noted would have died of this condition, 
it is not impossible. The enrichment of the review data set 
with these cases could also have led to overfitting of the 
WS. For this WS development study, we limited the age 
range of cases to between 1 and 49 years to ensure that we 
detected premature mortality and to avoid confounding 
from competing symptoms that may be seen in older 
people who likely have multiple comorbidities. We may 
have missed cases in older deaths, and how this WS 
performs in older age groups needs to be the subject of 
separate study. As in the development of InterVA-4, we, a 
priori, decided to use clinical knowledge to guide choice 
of our input variables of our model. While we argue that 
this is a reasonable method for model development, an 
alternative approach could have been to assess all VA vari-
ables for association and include all those that are statis-
tically significant regardless of clinical validity. Lastly, VA 
tools to ascertain cause of death are not as accurate as vital 
statistics reporting which is based on clinical diagnoses. 
However, such reporting is lacking in many populations, 
especially in LMICs. In these situations, VA is proven to 
be a reliable alternative method of ascertaining cause of 
death.
In summary, we have found that the InterVA-4 algo-
rithm performs poorly in detecting cases of deaths 
due to uncontrolled hyperglycaemia. Our algorithm 
improves detection, however is dominated by necessity 
for a premortem diagnosis of diabetes with other vari-
ables adding little discrimination. We also found that a 
high proportion of deaths due to uncontrolled hyper-
glycaemia received a diagnosis in their final illness. In 
countries where information on numbers of deaths due 
to uncontrolled hyperglycaemia is lacking and where VA 
reports exist, our algorithm can be used to give an indi-
cation of the numbers of deaths due to the condition, 
hence expose health system gaps in the provision of care 
which would result in earlier diagnosis and treatment.
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